electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

Rhea-AI Summary

electroCore, Inc. (Nasdaq: ECOR) announced the issuance of U.S. Patent No. 11,839,764 by the United States Patent and Trademark Office. The patent is related to a system for stimulating a nerve target in the head or neck of a patient for the treatment of various disorders, including primary headache. It involves a downloadable software program on a mobile device that controls the electrical impulses delivered by a stimulator to target nerves in the head or neck. This strengthens the company's intellectual property portfolio and positions them for the development of next-generation application-enabled products and devices.

Positive

• Issuance of a new patent strengthens the company's intellectual property portfolio
• The patent is related to a system for stimulating a nerve target in the head or neck of a patient for the treatment of various disorders, including primary headache
• The system involves a downloadable software program on a mobile device that controls the electrical impulses delivered by a stimulator to target nerves in the head or neck

Negative

• None.

ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a system for stimulating a nerve target in the head or neck of a patient for treatment of various disorders, such as primary headache.

U.S. Patent No. 11,839,764 entitled “Systems and Methods for Treating a Medical Condition with an Electrical Stimulation Treatment Regimen” was issued on December 12, 2023, and is generally related to a system including a downloadable software program on, for example, a mobile device, that is configured to control a parameter of the electrical impulses delivered by a stimulator for targeting nerves in the head or neck of a patient to treat various disorders such as primary headache, among others.

“We continue to grow our intellectual property portfolio,” stated Joshua Lev, Chief Strategy Officer of electroCore. “This new patent strengthens our position around systems that utilize mobile applications to control stimulators that treat various disorders such as primary headache, which may be useful as we develop our next generation application enabled products and devices.”

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans including potential commercial applications of nVNS and treatment paradigms; its pipeline or potential markets for its technologies including systems related to stimulating nerve targets at the head of a patient for treatment of various disorders; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of U.S. and international patents, including patents related to non-invasive nerve stimulation with mobile devices, providing expanded IP coverage; the possibility of future business models, the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov.

Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com

FAQ

What is the latest announcement from electroCore, Inc. (Nasdaq: ECOR)?

electroCore, Inc. (Nasdaq: ECOR) has announced the issuance of U.S. Patent No. 11,839,764 by the United States Patent and Trademark Office.

What is the patent related to?

The patent is related to a system for stimulating a nerve target in the head or neck of a patient for the treatment of various disorders, including primary headache.

What does the system involve?

The system involves a downloadable software program on a mobile device that controls the electrical impulses delivered by a stimulator to target nerves in the head or neck.

Who commented on the new patent issuance?

Joshua Lev, Chief Strategy Officer of electroCore, commented on the new patent issuance.

What is the significance of the new patent for electroCore, Inc. (Nasdaq: ECOR)?

The issuance of the new patent strengthens the company's intellectual property portfolio and positions them for the development of next-generation application-enabled products and devices.